Is Integer Holdings (ITGR) overvalued or fairly valued?

MarketChacha shows Integer Holdings's valuation in context — a trailing P/E of about 37.7, a forward P/E of about 18.2, a price-to-book of about 2.5 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

Does Integer Holdings's reported profit turn into cash?

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash. MarketChacha computes this cash-conversion check (1.86×) from reported figures — education, not a rating.

What is Integer Holdings's revenue?

Integer Holdings reported revenue of $1.9B for FY2025, with net profit of $102.8M, per official filings.

What is the share price of Integer Holdings (ITGR)?

Integer Holdings last traded at $125.23 (+0.1% on the day), as of 8/19/2026 — a delayed quote shown for education, not investment advice.

Integer Holdings

ITGR · NYSE · Healthcare · United States

Snapshot

TickerITGR

ExchangeNYSE

SectorHealthcare

IndustryMedical Devices

CountryUnited States

Employees11,000

HeadquartersPlano, United States

Websitewww.integer.net

Filings tracked15

About Integer Holdings

Integer Holdings Corporation operates as a medical device contract development and manufacturing company in the United States, Costa Rica, Puerto Rico, Ireland, and internationally. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures. It also provides cardiac rhythm management products, including implantable pacemakers, implantable cardioverter defibrillators, insertable cardiac monitors, implantable cardiac pacing and defibrillation leads, and heart failure therapies; implanted medical devices, implanted leads, procedure accessories, and external devices; neuromodulation products, such as implantable spinal cord stimulators; and non-rechargeable batteries, feedthroughs, device enclosures, machined components, and lead components and sub-assemblies. In addition, the company offers rechargeable batteries and chargers; orthopedics, minimally invasive surgery, and general surgery devices; and portable medical devices, including patient monitoring, ventilators, portable defibrillators, portable ultrasound, and X-Ray machines. Furthermore, the company provides medical technologies; supplies medical stamped components, and shallow and deep draw casings and assemblies; and epicardial pacing leads. It serves multi-national original equipment manufacturers and affiliated subsidiaries in the cardiac rhythm management, neuromodulation, orthopedics, cardio and vascular, and advanced surgical and portable medical markets. The company provides its products under the Greatbatch Medical and the Lake Region Medical brands. The company was formerly known as Greatbatch, Inc. and changed its name to Integer Holdings Corporation in July 2016. Integer Holdings Corporation was founded in 1970 and is headquartered in Plano, Texas.

Who owns it

Insiders1.4%
Institutions98.6%
Public & other0.0%

443 institutional holders

Ownership breakdown from public market data.

Top holders

Blackrock Inc.15.75%
Invesco Ltd.6.61%
Vanguard Portfolio Management LLC6.00%
Dimensional Fund Advisors LP4.79%
Nomura Holdings Inc.4.57%
Vanguard Capital Management LLC4.51%
State Street Corporation4.16%
Morgan Stanley3.96%

Largest institutional holders — last updated 6/30/2026.

Forensic scorecard

Latest ROE of 5.9% is on the low side — the business earns a modest return on shareholder capital.

Cash conversion1.86×

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash.

Net margin trend5.8% → 5.5%

Margin has held broadly steady over the period — stable profitability.

Return on equity5.9%

Latest ROE of 5.9% is on the low side — the business earns a modest return on shareholder capital.

Growth qualityrev 9% · PAT 6%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $465.3M · EPS 1.79

Est. earnings growth +1.6%

Next fiscal year

Rev $1.9B · EPS 6.87

Est. earnings growth +11.5%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Revenue (FY2025)

$1.9B

Net margin

5.5%

ROE

5.9%

Revenue CAGR (2y)

+9.2%

Profit CAGR (2y)

+6.5%

EPS (FY2025)

2.89

Net profit (FY2025)

$102.8M

Ask MarketChacha about ITGR

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2025	$1.9B	$102.8M	2.89	5.5%	5.9%
FY2024	$1.7B	$119.9M	3.36	7.0%	7.4%
FY2023	$1.6B	$90.7M	2.69	5.8%	6.0%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q3	$464.1M	$23.6M	0.69	5.1%
2026Q2	$439.6M	$16.5M	0.48	3.8%
2025Q3	$467.7M	$39.7M	1.11	8.5%
2025Q2	$476.5M	$37.0M	1.04	7.8%
2025Q1	$437.4M	$-22.5M	-0.66	-5.1%
2024Q3	$431.4M	$35.4M	0.99	8.2%
2024Q2	$427.9M	$31.2M	0.88	7.3%
2024Q1	$407.8M	$20.5M	0.59	5.0%
2023Q3	$396.8M	$27.3M	0.81	6.9%
2023Q2	$400.0M	$24.0M	0.71	6.0%
2023Q1	$378.8M	$13.1M	0.39	3.4%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

8-K — Material agreement, Bylaw/charter change, Exhibits
SEC8/4/2026material
10-Q filing
SEC8/4/2026
8-K — Reg FD disclosure, Exhibits
SEC8/3/2026material
8-K — Results of operations, Exhibits
SEC8/3/2026material
8-K — Executive/director change
SEC6/26/2026material
8-K — Executive/director change, Shareholder vote results, Exhibits
SEC5/22/2026material
8-K — Results of operations, Reg FD disclosure, Exhibits
SEC4/30/2026material
10-Q filing
SEC4/30/2026
8-K — Material agreement, Executive/director change, Reg FD disclosure, Exhibits
SEC3/12/2026material
10-K filing
SEC2/23/2026
8-K — Results of operations, Reg FD disclosure, Exhibits
SEC2/19/2026material

2025

8-K — Other events, Exhibits
SEC11/4/2025material
8-K — Executive/director change, Reg FD disclosure, Exhibits
SEC10/24/2025material
8-K — Results of operations, Reg FD disclosure, Exhibits
SEC10/23/2025material
10-Q filing
SEC10/23/2025

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.